Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Craig Horbinski

Showing results (191-200 of 209) with videos related to

Pageof 21
Sort By:
Neuro-Oncology|July 19, 2024
Fc-enhanced anti-CTLA-4, anti-PD-1, doxorubicin, and ultrasound-mediated blood-brain barrier opening: A novel combinatorial immunotherapy regimen for gliomasKwang-Soo Kim, Karl Habashy, Andrew Gould, et al.
Neuro-Oncology|October 14, 2022
Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directionsJulie J Miller, L Nicolas Gonzalez Castro, Samuel McBrayer, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 5, 2020
Central Nervous System Cancers, Version 3.2020, NCCN Clinical Practice Guidelines in OncologyLouis Burt Nabors, Jana Portnow, Manmeet Ahluwalia, et al.
Nature Communications|October 7, 2023
Super-enhancer hijacking drives ectopic expression of hedgehog pathway ligands in meningiomasMark W Youngblood, Zeynep Erson-Omay, Chang Li, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 12, 2023
NCCN Guidelines® Insights: Central Nervous System Cancers, Version 2.2022Craig Horbinski, Louis Burt Nabors, Jana Portnow, et al.
Science Translational Medicine|March 11, 2021
A first-in-human phase 0 clinical study of RNA interference-based spherical nucleic acids in patients with recurrent glioblastomaPriya Kumthekar, Caroline H Ko, Tatjana Paunesku, et al.
Acta Neuropathologica|October 22, 2022
Expanded analysis of high-grade astrocytoma with piloid features identifies an epigenetically and clinically distinct subtype associated with neurofibromatosis type 1Patrick J Cimino, Courtney Ketchum, Rust Turakulov, et al.
Nature Medicine|August 21, 2024
Molecular classification to refine surgical and radiotherapeutic decision-making in meningiomaJustin Z Wang, Vikas Patil, Alexander P Landry, et al.
Nature Cancer|February 5, 2022
ERK1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastomaVíctor A Arrieta, Andrew X Chen, J Robert Kane, et al.
Nature Cancer|February 12, 2022
Publisher Correction: ERK1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastomaVíctor A Arrieta, Andrew X Chen, J Robert Kane, et al.
Pageof 21

Showing results (191-200 of 209) with videos related to

Sort By:
Pageof 21
Neuro-Oncology|July 19, 2024
Fc-enhanced anti-CTLA-4, anti-PD-1, doxorubicin, and ultrasound-mediated blood-brain barrier opening: A novel combinatorial immunotherapy regimen for gliomasKwang-Soo Kim, Karl Habashy, Andrew Gould, et al.
Neuro-Oncology|October 14, 2022
Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directionsJulie J Miller, L Nicolas Gonzalez Castro, Samuel McBrayer, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 5, 2020
Central Nervous System Cancers, Version 3.2020, NCCN Clinical Practice Guidelines in OncologyLouis Burt Nabors, Jana Portnow, Manmeet Ahluwalia, et al.
Nature Communications|October 7, 2023
Super-enhancer hijacking drives ectopic expression of hedgehog pathway ligands in meningiomasMark W Youngblood, Zeynep Erson-Omay, Chang Li, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 12, 2023
NCCN Guidelines® Insights: Central Nervous System Cancers, Version 2.2022Craig Horbinski, Louis Burt Nabors, Jana Portnow, et al.
Science Translational Medicine|March 11, 2021
A first-in-human phase 0 clinical study of RNA interference-based spherical nucleic acids in patients with recurrent glioblastomaPriya Kumthekar, Caroline H Ko, Tatjana Paunesku, et al.
Acta Neuropathologica|October 22, 2022
Expanded analysis of high-grade astrocytoma with piloid features identifies an epigenetically and clinically distinct subtype associated with neurofibromatosis type 1Patrick J Cimino, Courtney Ketchum, Rust Turakulov, et al.
Nature Medicine|August 21, 2024
Molecular classification to refine surgical and radiotherapeutic decision-making in meningiomaJustin Z Wang, Vikas Patil, Alexander P Landry, et al.
Nature Cancer|February 5, 2022
ERK1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastomaVíctor A Arrieta, Andrew X Chen, J Robert Kane, et al.
Nature Cancer|February 12, 2022
Publisher Correction: ERK1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastomaVíctor A Arrieta, Andrew X Chen, J Robert Kane, et al.
Pageof 21